Loading...
Loading...
AQST| Name | Value |
|---|---|
| Revenues | 12.1M |
| Cost of Revenue | 4.4M |
| Gross Profit | 7.7M |
| Operating Expense | 16.6M |
| Operating I/L | -9.0M |
| Other Income/Expense | -3.9M |
| Interest Income | 0.3M |
| Pretax | -12.8M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -12.8M |
Aquestive Therapeutics, Inc. is a pharmaceutical company that develops and commercializes innovative products to address unmet medical needs. The company's portfolio includes Sympazan for lennox-gastaut syndrome, Suboxone for opioid dependence, Zuplenz for nausea and vomiting, and Azstarys for attention deficit hyperactivity disorder. Additionally, Aquestive's proprietary product candidates, such as Libervant and Exservan, target the treatment of seizures and amyotrophic lateral sclerosis. The company also has a pipeline of complex molecule products, including AQST-108, AQST-305, and AQST-109, as well as KYNMOBI for Parkinson's disease. Aquestive Therapeutics generates revenue through the sales of its pharmaceutical products and potential future product launches.
